BMRN BioMarin Pharmaceutical Inc.

76.5
+4.77  (+7%)
Previous Close 71.73
Open 72.51
Price To Book 4.64
Market Cap 13,728,901,064
Shares 179,462,759
Volume 1,861,165
Short Ratio
Av. Daily Volume 1,232,147

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 interim data released May 28, 2019 - Factor VIII level =36 (23 to 26 weeks).
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
Phase 3 top-line data due end of 2019.
Vosoritide
Achondroplasia
Approval announced May 24, 2018.
Palynziq (Pegvaliase)
Phenylketonuria (PKU)
Program terminated June 2016
Reveglucosidase alfa (BMN 701)
Pompe Disease
Approved February 14, 2014.
Vimizim (GALNS)
(MPS IVA) Morquio A Syndrome
PDUFA date extended by three months to April 27 2017. Approval announced April 27, 2017.
Cerliponase alfa
Batten Disease
CRL issued January 14, 2016.
Kyndrisa
Duchenne Muscular Dystrophy (DMD)
BLA filing due 4Q 2019.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
Phase 1/2 dosing has commenced - noted May 15, 2018.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A with with pre-existing AAV5 antibodies
Phase 3 top-line data due end of 2019.
Vosoritide
Achondroplasia - young children

Latest News

  1. Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 31% Discount?
  2. The $200K Club: NetApp's median employee gets a pay boost to join the salary ranks of Google, Netflix and Facebook
  3. 6 Underperforming Stocks in Gurus' Portfolios
  4. Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval
  5. Edited Transcript of BMRN earnings conference call or presentation 1-Aug-19 8:30pm GMT
  6. BioMarin's Roller Coaster Continues
  7. Biomarin Pharmaceutical Inc (BMRN) Q2 2019 Earnings Call Transcript
  8. BioMarin (BMRN) Shares Down on Q1 Earnings & Sales Miss
  9. BioMarin Stock Dropped After Hours on Weak Earnings, but Analysts Aren’t Worried
  10. BioMarin Pharmaceutical (BMRN) Lags Q2 Earnings and Revenue Estimates
  11. BioMarin Announces Second Quarter 2019 Financial Results
  12. Rate Cut Wait Almost Over
  13. What's in the Cards for Sarepta (SRPT) This Earnings Season?
  14. BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
  15. Health Care Digest: Why 2020 could be big for women's health, Trump's kidney order — and more
  16. BioMarin to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1 at 4:30pm ET
  17. See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
  18. Shake-Up in Big Weed
  19. BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shift From Loss To Profit
  20. JP Morgan: 2 Gene Therapy Stocks to Buy Now